Maintenance Capecitabine After mFOLFIRINOX Improves PFS in Metastatic Pancreatic Cancer

This small phase II randomized trial informs whether an oral fluoropyrimidine maintenance strategy after induction mFOLFIRINOX offers a practical benefit for pharmacists managing metastatic pancreatic adenocarcinoma.

📅 Journal publication: Sep 1, 2026 · Last updated: Oct 12, 2026

capecitabinemodified FOLFIRINOXfluoropyrimidinemaintenance therapymetastatic pancreatic cancerpancreatic ductal adenocarcinomaphase II trialPFSOSquality of lifehand-foot syndrome Oncology Pharmacy

Background Information

Capecitabine maintenance boosts survival in metastatic pancreatic cancer.

Metastatic pancreatic cancer (mPC) has limited treatment options and poor prognosis. Exploring effective maintenance therapies is critical for improving outcomes. Capecitabine maintenance therapy improved progression-free survival (PFS) to 6.13 months and overall survival (OS) to 14.20 months compared to observation alone. Maintenance capecitabine post-FOLFIRINOX may offer a valuable therapeutic strategy for mPC with acceptable safety and extended survival, requiring further validation in larger trials. Capecitabine maintenance post-FOLFIRINOX extends survival in metastatic pancreatic cancer.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Shehata MA, Alhanafy AM, Hassan ME, Shaaban NA, Hegazy AH

Citation: Shehata MA, Alhanafy AM, Hassan ME, et al. Evaluation of Maintenance Capecitabine Therapy After First-Line Chemotherapy in Metastatic Pancreatic Cancer. Asian Pacific journal of cancer prevention : APJCP. 2026;27(9):3203-3212. doi:10.31557/APJCP.2026.27.9.3203

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →